Country, year | Canada, 2010 | Partner B, 2010 | Partner A, 2011 | France, 2012 | Germany, 2013 | Italy-TA, 2013 | Italy-TF, 2013 | Spain, 2013 |
---|---|---|---|---|---|---|---|---|
N | 339 | 179 | 348 | 3195 | 1318 | 774 | 1007 | 883 |
Age (years) | 81±8 | 83.1±8.6 | 83.6±6.8 | 82.7±7.2 | 81.7±6.1 | 81.0±6.7 | 81.2±5.6 | 81.4±6 |
Male | 152 (44.8) | 82 (45.8) | 201 (57.8) | 1630 (51.0) | 547/1318 (39.3) | 328 (42.4) | 452 (44.9) | 421 (47.7) |
Hypertension | 252 (74.3) | – | – | – | – | 671 (86.7) | – | 687 (77.8) |
Diabetes | 79 (23.3) | – | – | – | 448/1314 (34.1) | 205 (26.5) | 280 (27.8) | 314 (35.6) |
Atrial fibrillation | 115 (33.9) | 28/85 (32.9) | 80/196 (40.8) | 820/3083 (26.6) | 327/1313 (24.9) | 169 (21.8) | 171 (17.0) | 254 (28.8) |
COPD | 100 (29.5) | 74 (41.3) | 151 (43.4) | 790/3093 (25.5) | 369/1315 (28.1) | 247 (31.9) | 231 (22.9) | NA |
CAD (prior MI*) | 234 (69.0) | 121 (67.6) | 260 (74.9) | 1483/3093 (47.9) | – | 382 (49.4) | 218 (21.6)* | 365/666 (54.8) |
Previous CABG (previous cardiac surgery*) | 116 (34.2) | 58/155 (37.4) | 147 (42.6) | 564/3093 (18.2) | 240/1318 (18.2) | 87 (11.2) 167 (21.6)* | – | 94 (10.6) |
Cerebrovascular disease, prior stroke* | 77 (22.7) | 48 (27.4) | 95 (29.3) | 308/3093 (10.0) | 107/1315 (8.1)* | 66 (8.5) | 70 (6.9)* | 95 (10.8) |
Peripheral vascular disease | 120 (35.4) | 54 (30.3) | 148 (43.0) | 643/3093 (20.8) | 273/1315 (20.8) | 384 (49.6) | 193 (19.2) | 138 (15.6) |
Prior pacemaker | – | 35/153 (22.9) | 69 (20.0) | 447/3135 (14.3) | 44 (5.7) | – | 62 (7.0) | |
Renal function (mL/min/m²) (renal failure†) | 59.3±24.2 188 (55.5)† | – | – | – | 798/1318 (60.5)† | 47.4±24.9 | 47.1±22.2 | 48.2±22.1 683 (77.3)† |
NYHA III/IV | 308 (90.9) | 165 (92.2) | 328 (94.3) | – | 1156/1309 (88.3) | 621 (80.2) | 701 (69.6) | 644 (72.9) |
STS-PROM (%) | 9.8±6.4 | 11.2±5.8 | 11.8±3.3 | 14.4±11.9 | – | 10.6±8.5 | 8.0±2.4 | NA |
Logistic EuroSCORE (%) | 27.7±16.3 | 26.4±17.2 | 29.3±16.5 | 21.9±14.3 | 20.3±13.2 | 25.6±16.3 | 23.1±14.1 | 17.4±11.3 |
Pulmonary hypertension | 84 (25.0) | 50/118 (42.4) | 125/295 (42.4) | 478/2435 (19.6) | – | 42.8±13.0 | 172 (17.1) | 133/536 (24.8) |
LVEF (%) | 55±14 | 53.9±13.1 | 52.5±13.5 | 53.2±14.1 | 53.5±14.5 | 52.9±12.8 | 51.5±11.9 | 56.4±13.3 |
Mean aortic gradient (mm Hg) | 46±17 | 44.5±15.7 | 42.7±14.6 | 48.1±16.5 | 49.7±19.3 | 49.8±15.4 | 44.6±13.4 | 49.7±14.9 |
Aortic valve area (cm²) | 0.63±0.17 | 0.6±0.2 | 0.7±0.2 | 0.7±0.2 | 0.68±0.40 | 0.48±0.13 | – | 0.60±0.21 |
Moderate or severe MR | 27 (8.0) | 38 (22.6) | 65 (19.6) | 661 (20.7) | 42 (3.2) | 199 (25.7) | 337 (33.5) | 55 (6.2) |
†Glomerular filtration rate <60 mL/min/m².
CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD: chronic obstructive pulmonary disease; MI, myocardial infarction; MR, mitral regurgitation; NA, not available; NYHA, New York Heart Association; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality.